\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
CAMBRIDGE, Mass. , October 17, 2022–(BUSINESS WIRE)–VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company focused on immunology in the pursuit of prevention and treatment of difficult diseases, announced that Jeff Baxter, president and CEO of VBI, and David E. Anderson, Ph. D. , scientific director of VBI, will participate in an analyst-led fireplaceside verbal exchange at H. C. Wainwright’s 3rd annual hepatitis B virus (HBV) conference on Tuesday, October 18, 2022.
Presentation details
Event: H. C. Wainwright’s 3rd Annual Hepatitis B Virus (HBV) Conference Date: Tuesday, October 18, 2022 Time: from nine a. m. m. a nine: 30 a. m. ET
There will be a live webcast of the presentation on the investor page of VBI’s online page at: https://www. vbivaccines. com/investors/events-and-presentations/. A reproduction of the webcast will be archived on the company’s website after the submission.
About VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company led by immunology in the pursuit of the prevention and treatment of difficult diseases. Through its cutting-edge virus-like particle (“VLP”) approach, adding platform (“eVLP”), VBI is presenting candidates for vaccines that mimic the herbal presentation of viruses, designed to elicit the innate force of the human immune system. VBI is committed to attacking and defeating vital infectious diseases, aggregating and cytomegalovirus (CMV), as well as competitive cancers, in addition to glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with studio operations in Ottawa, Canada, and a studio/production facility in Rehovot, Israel. For more information, visit www. . vbivaccines. com.
Cautionary Note Regarding Forward-Looking Information Certain statements contained in this press release that are forward-looking and not statements of past fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are statements forward-looking forward-looking data within the meaning of Canadian securities legislation (collectively, “forward-looking statements”). The Company cautions that such statements involve dangers and uncertainties that may also materially affect the effects of the Company’s operations. These forward-looking statements are based on control’s ideals, as well as the assumptions made through control and the data that exist to obtain it. Actual effects may also differ materially from those weighted through forward-looking statements due to certain factors, including, but not limited to, the impact of general economic, political or publicity situations in the United States or internationally. ; the effect of the current COVID-19 pandemic on our clinical studies, manufacturing, business plan and the global economy; the ability to effectively manufacture and advertise PreHevbrio/PreHevbri; the ability to identify potential products as effective or safe in preclinical or clinical trials; the ability to identify or maintain collaborations on the progression of candidate projects and PreHevbrio/PreHevbri publicity; the ability to download appropriate or mandatory regulatory approvals to advertise potential products; the ability to offload long-term financing for progression and working capital products and to offload such financing on moderate advertising terms; the Company’s ability to manufacture product applicants on an advertising scale or in collaboration with third parties; adjustments in the duration and nature of the competitors; the ability to retain key executives and scientists; and the ability to secure and enforce similar legal rights to the Company’s products. A discussion of those and other factors, aggregating dangers and uncertainties relating to the Company, is set forth in the Company’s filings with the SEC and Canadian securities regulators, adding its Annual Report on Form 10. -K filed with the SEC on March 7, 2022, and filed with the Canadian Security Government on sedar. com on March 7, 2022, as possibly supplemented or amended through the company’s quarterly reports on Form 10-Q. Given these dangers, uncertainties and factors, you are cautioned not to place undue reliance on those forward-looking statements, which are qualified in their entirety by this cautionary statement. All forward-looking statements made in this document are based on our existing expectations and we assume no legal responsibility or duty to update or revise any forward-looking statement for any reason, except as required by law.
View businesswire. com edition: https://www. businesswire. com/news/home/20221017005335/en/
Contacts
IBC
Nicole AndersonDirector of Corporate Communications